company background image
0RC6 logo

Pharma Mar LSE:0RC6 Stock Report

Last Price

€28.04

Market Cap

€494.6m

7D

-1.9%

1Y

-37.8%

Updated

25 Mar, 2024

Data

Company Financials +

0RC6 Stock Overview

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, France, rest of EU, the United States, and internationally.

0RC6 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance1/6
Financial Health4/6
Dividends1/6

Pharma Mar, S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Pharma Mar
Historical stock prices
Current Share Price€28.04
52 Week High€45.46
52 Week Low€27.86
Beta-0.018
1 Month Change-13.07%
3 Month Change-34.58%
1 Year Change-37.78%
3 Year Change-71.68%
5 Year Change56.09%
Change since IPO-40.82%

Recent News & Updates

Recent updates

Shareholder Returns

0RC6GB BiotechsGB Market
7D-1.9%3.2%2.4%
1Y-37.8%-27.1%4.2%

Return vs Industry: 0RC6 underperformed the UK Biotechs industry which returned -27.1% over the past year.

Return vs Market: 0RC6 underperformed the UK Market which returned 4.2% over the past year.

Price Volatility

Is 0RC6's price volatile compared to industry and market?
0RC6 volatility
0RC6 Average Weekly Movement3.9%
Biotechs Industry Average Movement7.9%
Market Average Movement4.7%
10% most volatile stocks in GB Market11.3%
10% least volatile stocks in GB Market2.5%

Stable Share Price: 0RC6's share price has been volatile over the past 3 months.

Volatility Over Time: 0RC6's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1986509Jose Fernandez Sousa-Farohttps://www.pharmamar.com

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, France, rest of EU, the United States, and internationally. The company operates through Oncology and RNA interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca for treating patients with small cell lung cancer.

Pharma Mar, S.A. Fundamentals Summary

How do Pharma Mar's earnings and revenue compare to its market cap?
0RC6 fundamental statistics
Market cap€494.62m
Earnings (TTM)€1.14m
Revenue (TTM)€158.15m

435.0x

P/E Ratio

3.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0RC6 income statement (TTM)
Revenue€158.15m
Cost of Revenue€9.61m
Gross Profit€148.54m
Other Expenses€147.40m
Earnings€1.14m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0.064
Gross Margin93.92%
Net Profit Margin0.72%
Debt/Equity Ratio20.6%

How did 0RC6 perform over the long term?

See historical performance and comparison

Dividends

2.3%

Current Dividend Yield

1,023%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.